S&P Futures
4,159.50-5.25(-0.13%)Dow Futures
33,982.00-34.00(-0.10%)Nasdaq Futures
13,905.25-14.00(-0.10%)
Franklin Growth Series Class A (FKGRX)
| Previous Close | 143.84 |
| YTD Return | 6.51% |
| Expense Ratio (net) | 0.82% |
| Category | Large Growth |
| Last Cap Gain | 0.00 |
| Morningstar Rating | ★★★★★ |
| Morningstar Risk Rating | Below Average |
| Sustainability Rating |
| Net Assets | 20.44B |
| Beta (5Y Monthly) | 1.00 |
| Yield | 0.12% |
| 5y Average Return | N/A |
| Holdings Turnover | 9.01% |
| Last Dividend | 0.18 |
| Average for Category | N/A |
| Inception Date | Apr 01, 1948 |
- CNW Group
Media Advisory - Eastern Ontario Regional Network (EORN) to make an announcement related to cellular connectivity
PETERBOROUGH COUNTY, ON, March 17, 2021 /CNW/ - Members of the accredited media are invited to join the Eastern Ontario Regional Network (EORN) for an announcement about cellular connectivity. Other participants include: The Honourable Maryam Monsef, Canada's Minister for Women and Gender Equality and Rural Economic Development; The Honourable Laurie Scott, Ontario's Minister of Infrastructure; Warden J.
- CNW Group
Tetra Bio-Pharma Announces Closing of Bought Deal Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/OTTAWA, ON, March 2, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development, is pleased to announce it has closed its previously announced bought-deal public offering of units (the "Units") of the Company.
- ACCESSWIRE
Tetra Bio-Pharma To Monetize Its Dronabinol And Botanical Product Portfolios
Company signs LOI for Nordics and GermanyOTTAWA, ON / ACCESSWIRE / February 25, 2021 /Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced the signing of a Letter of Intent with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa® and QIXLEEF™ in Denmark, Norway, Sweden, Finland, and Germany.
